Calla Lily Clinical Care develops advanced drug delivery systems specifically for gynecological applications. Their patented Callavid® platform technology addresses current limitations in vaginal drug administration by offering a leak-free solution. This innovation aims to improve patient adherence and confidence across fertility, pregnancy support, and other women's health conditions.
Funding
$3.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods of vaginal drug delivery are inadequate for many women, leading to medication leakage, inaccurate dosing, and user inconvenience. This is especially problematic for treatments related to fertility, pregnancy support, and gynecological conditions.
Solution
Calla Lily Clinical Care offers the Callavid platform, a patented intravaginal drug delivery system designed to improve dosage accuracy and user experience. The Callavid technology minimizes medication leakage, ensuring that women receive the intended dose of medication. This platform supports various applications, including miscarriage prevention, IVF luteal phase management, and the delivery of treatments for other gynecological conditions, offering a more reliable and convenient alternative to traditional methods.
Target Audience
The primary target audience includes women undergoing fertility treatments, those at risk of miscarriage, and individuals requiring intravaginal drug delivery for gynecological health, as well as the clinicians who treat them.
Features
- Leak-free vaginal drug delivery system for accurate dosing
- User-friendly design for convenient self-administration
- Suitable for progesterone and other vaginally-delivered medications
- Addresses patient concerns about leakage and messiness
- May reduce psychological trauma, anxiety, and depression associated with medication leakage